Spironolactone Use is Associated with Better Survival in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) with Concomitant Angiotensin Receptor Blocker Treatment
SSRN Electronic Journal2023
Xiao Liu, Yue Wang, Hong Pan, Yuan Jiang, Zhengyu Cao, Maoxiong Wu, Zhiteng Chen, Ayiguli Abudukeremu, Zhiwei Yan, Jianyong Ma, Wengen Zhu, Yangxin Chen, Kai‐Hang Yiu, Yuling Zhang, Jingfeng Wang
Related Papers
- → Role of spironolactone in the treatment of heart failure with preserved ejection fraction(2018)23 cited
- → Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT2 receptor?(2008)47 cited
- → Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones(1992)68 cited
- → TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?(2013)4 cited
- → Inhibition of the expression of the gene for the angiotensin AT1 receptor by angiotensin II in the rat adrenal gland(1998)8 cited